Featured Research

from universities, journals, and other organizations

Estrogen-progestin Menopausal Hormone Therapy And Risk Of Lobular And Tubular Breast Cancer

Date:
February 20, 2006
Source:
BioMed Central
Summary:
Estrogen-progestin menopausal hormone therapy is associated with a more than two-fold higher relative risk of developing lobular cancer or tubular cancer than of developing ductal cancer. The results of a large European study published today in the journal 'Breast Cancer Research' show for the first time that estrogen-progestin therapy is associated with a higher relative risk of developing tubular cancer than ductal cancer, when taken for more than five years.

Estrogen-progestin menopausal hormone therapy is associated with a more than two-fold higher relative risk of developing lobular cancer or tubular cancer than of developing ductal cancer. The results of a large European study published today in the journal Breast Cancer Research show for the first time that estrogen-progestin therapy is associated with a higher relative risk of developing tubular cancer than ductal cancer, when taken for more than five years. The study also confirms previous findings that estrogen-progestin therapy is associated with a higher relative risk of lobular cancer than ductal cancer.

Related Articles


Lena Rosenberg from the Karolinska Institutet in Stockholm, Sweden and colleagues from the Karolinska Institutet and the Genome Institute of Singapore carried out a population-based case-control study of women recently diagnosed with invasive breast cancer. They selected 1,888 women with ductal breast cancer, 308 women with lobular cancer and 93 women with tubular breast cancer. All women were matched for age with 3,065 women randomly selected from the population, acting as controls. Both patients and controls were asked to fill in a questionnaire about their medical history, health status and use of menopausal hormone therapy.

Rosenberg et al.'s results show that women who used medium potency estrogen-progestin combination therapy had a higher risk of developing lobular or tubular breast cancer than of developing ductal cancer, compared with women who did not use hormone therapy. The risk of developing any of the cancers was higher for women who had used the therapy for more than five years. For these women, the risk of developing tubular cancer (OR 6.5, 95% confidence interval 2.8-14.9) or lobular cancer (OR 5.6, 95% confidence interval 3.2-9.7) was more than twice the risk of developing ductal cancer (OR 2.3, 95% confidence interval 1.6-3.3).

Other factors, such as the number of births, age at menopause or body mass index, were found to be associated with a similar risk of developing the three subtypes of breast cancer.

###

Article:

Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological types of breast cancer: a case-control study
Lena U Rosenberg, Cecilia Magnusson, Emma Lindstrom, Sara Wedren, Per Hall and Paul W Dickman
Breast Cancer Research 2006, 8:R11 (17 February 2006) doi:10.1186/bcr1378


Story Source:

The above story is based on materials provided by BioMed Central. Note: Materials may be edited for content and length.


Cite This Page:

BioMed Central. "Estrogen-progestin Menopausal Hormone Therapy And Risk Of Lobular And Tubular Breast Cancer." ScienceDaily. ScienceDaily, 20 February 2006. <www.sciencedaily.com/releases/2006/02/060220101752.htm>.
BioMed Central. (2006, February 20). Estrogen-progestin Menopausal Hormone Therapy And Risk Of Lobular And Tubular Breast Cancer. ScienceDaily. Retrieved March 30, 2015 from www.sciencedaily.com/releases/2006/02/060220101752.htm
BioMed Central. "Estrogen-progestin Menopausal Hormone Therapy And Risk Of Lobular And Tubular Breast Cancer." ScienceDaily. www.sciencedaily.com/releases/2006/02/060220101752.htm (accessed March 30, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, March 30, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
WH Plan to Fight Antibiotic-Resistant Germs

WH Plan to Fight Antibiotic-Resistant Germs

AP (Mar. 27, 2015) The White House on Friday announced a five-year plan to fight the threat posed by antibiotic-resistant bacteria amid fears that once-treatable germs could become deadly. (March 27) Video provided by AP
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins